Sacubitril/valsartan, an angiotensin receptor–neprilysin inhibitor (ARNI), is the first new drug to show mortality benefit for heart failure with reduced ejection fraction (HFrEF) in more than a decade. Based on a 20% reduction in cardiovascular death in patients who received it compared with those who received enalapril in the Prospective Comparison of ARNI With ACEI (Angiotensin-Converting Enzyme Inhibitors) to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF) trial,1 sacubitril/valsartan received expedited US Food and Drug Administration approval in 2015 and a class I American Heart Association/American College of Cardiology/Heart Failure Society of America guideline recommendation in 2016.2 However, clinical adoption remains slow, with less than 3% of patients with HFrEF receiving the drug as of 2016.3 Since more than 80% of deaths from heart failure occur in people older than 65 years,4 we examined Medicare Part D plans nationwide to explore whether high cost sharing or a lack of coverage could be barriers to the adoption of sacubitril/valsartan under Medicare Part D.
DeJong C, Kazi DS, Dudley RA, Chen R, Tseng C. Assessment of National Coverage and Out-of-Pocket Costs for Sacubitril/Valsartan Under Medicare Part D. JAMA Cardiol. Published online July 10, 20194(8):828–830. doi:10.1001/jamacardio.2019.2223
Browse and subscribe to JAMA Network podcasts!
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: